Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Brii Biosciences Limited ( (HK:2137) ) has shared an announcement.
Brii Biosciences Limited announced the results of its Annual General Meeting held on June 3, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements, re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors, which underscores the company’s stability and ongoing commitment to strong governance practices.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company incorporated in the Cayman Islands, focusing on developing innovative therapies for infectious diseases and other significant health challenges.
Average Trading Volume: 5,609,384
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.35B
For detailed information about 2137 stock, go to TipRanks’ Stock Analysis page.